Skip to main content

Table 4 Log-rank analysis of prognostic factors in cervical squamous cell carcinoma patients

From: Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma

Factor

PFS

OS

3-year (%)

χ 2

P-value

3-year (%)

χ 2

P-value

Age

(year)

≤54

84.91

3.963

0.047

88.66

2.392

0.122

> 54

64.52

67.74

Family history of cancer

No

71.70

1.884

0.170

75.47

1.618

0.203

Yes

100.00

100.00

History of miscarriage

No

66.67

2.299

0.129

74.07

0.945

0.331

Yes

80.33

80.33

Tumor size

(cm)

≤5

73.68

0.027

0.870

78.95

0.085

0.771

> 5

74.36

74.36

Tumor type

Cauliflower

76.74

0.214

0.644

76.74

0.033

0.857

Nodular

72.00

76.00

Hollow

57.14

71.43

Others

100.00

100.00

Histologic grade

Well

50.00

0.239

0.625

50.00

0.066

0.797

Moderate

75.31

80.25

Poor

66.67

66.67

Papillary

83.33

83.33

FIGO stage

IIB

82.46

1.271

0.260

82.46

1.166

0.280

IIIA-IIIB

72.41

65.52

SCC-Ag

Normal

90.00

1.854

0.173

90.00

1.367

0.242

Anormal

70.53

74.74

CEA

Normal

80.56

1.951

0.163

86.00

3.238

0.072

Anormal

62.79

62.79

TSGF

Normal

72.84

0.191

0.662

77.78

0.003

0.960

Anormal

76.47

76.47

Pelvic lymph nodes

No

79.59

1.698

0.193

79.59

0.571

0.450

Yes

69.70

75.76

HPV E1

Positive

85.29

5.307

0.021

91.18

8.078

0.004

Negative

57.45

57.45

Treatment

Radiotherapy + chemotherapy

78.13

1.073

0.300

81.25

0.265

0.607

Radiotherapy

68.63

72.55

  1. FIGO International Federation of Gynecology and Obstetrics, SCC-Ag Squamous cell carcinoma antigen, CEA carcinoembryonic antigen, TSGF Tumor specific growth factor, HPV Human papillomavirus